Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

EnBiotix

EnBiotix
2010 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$3.15M LATEST DEAL AMOUNT
2 INVESTORS
Description

Owner and operator of a bioengineering company intended to specialize in antibiotic development and combat the global rise of drug-resistant bacterial infections. The company designs synthetic-biological technologies towards the development of transformational anti-infective, personal care and medical products, enabling patients to avail low-cost drugs for chronic, recurrent, and life-threatening pulmonary infections.

Formerly Known As
Anagenix Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 197 West Springfield Street
  • Boston, MA 02118
  • United States

+1 (508) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore EnBiotix’s full profile, request a free trial.

EnBiotix Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 26-Sep-2019 $3.15M 00.000 000.00 Completed Generating Revenue
2. Corporate (Series A) 12-May-2016 000 000 000.00 Completed Generating Revenue
1. Grant 01-Jan-2016 $264K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

EnBiotix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00
Series A 2,200,000 $0.001000 5% $1.32 $1.32 1x $1.32 12.97%
To view this company’s complete Cap Table, request access »

EnBiotix Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spero Therapeutics Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 0&0
000000 000 Venture Capital-Backed Menlo Park, CA 00 00000 00000000000 00000
0000000000 Formerly VC-backed Yonkers, NY 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

EnBiotix Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000000 03-Nov-2016 000000000000000000 Drug Discovery 0000000 00000 00
To view this company’s complete investment and acquisition history, request access »

EnBiotix Subsidiaries (1)

Company Name Industry Location Founded
000 000000000000 Drug Discovery Leipzig, Germany 0000
To view this company’s complete subsidiary history, request access »

EnBiotix Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Apeiron Holdings Other Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

EnBiotix Executive Team (5)

Name Title Board
Seat
Contact
Info
Benjamin Perrone Director, Business Development & Finance
Michael Garrett Chief Business Officer
Dan Hartman MD Co-Founder & Board Member
James Collins Co-Founder
Jeffrey Wager MD Co-Founder, Chairman & Chief Executive Officer

EnBiotix Board Members (4)

Name Representing Role Since Contact
Info
Christopher Micetich Self Board Member 000 0000
Dan Hartman MD EnBiotix Co-Founder & Board Member 000 0000
Dennis Ausiello MD EnBiotix Board Member 000 0000
Jeffrey Wager MD Self Co-Founder, Chairman & Chief Executive Officer 000 0000